Spots Global Cancer Trial Database for Temsirolimus in Myelodysplastic Syndrome (MDS)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Temsirolimus in Myelodysplastic Syndrome (MDS)
Official Title: Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study
Study ID: NCT01111448
Conditions
Interventions
Study Description
Brief Summary: The goal of this Pilot-study is to evaluate the response of unselected MDS patients to temsirolimus a drug approved for the treatment of renal cell cancer. It is planned to give temsirolimus at a weekly dose of 25 mg as intravenous infusion for a maximum duration of 12 months. Regular bone marrow biopsies are planned for controlling MDS response.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Klinikum Chemnitz Klinik fĂźr Innere Medizin III, Chemnitz, , Germany
Universitätsklinikum C. G. Carus der TU Dresden, Dresden, , Germany
Universitätsklinikum Dßsseldorf Klinik fßr Hämatologie, Onkologie und Klin. Immunologie, Dßsseldorf, , Germany
Universitätsmedizin GÜttingen Georg-August-Universität Abteilung Hämatologie und Onkologie, Goettingen, , Germany
Universitätsklinikum Leipzig AÜR, Leipzig, , Germany
Forschungsgesellschaft mbH, Leipzig, , Germany
Klinikum Mannheim GmbH III. Medizinische Universitätsklinik -SP Hämatologie/Onkologie, Mannheim, , Germany
Contact Details
Name: Uwe Platzbecker, MD, PhD
Affiliation: Medizinische Klinik I, Universitätsklinikum Carl-Gustav-Carus, Dresden, Germany
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
